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Bcl-10-proteiini on normaalisti mukana NF-κB-välitteisessä signaalinvälitysketjussa, joka on tärkeä 
B-lymfosyyttien eloonjäännissä, erilaistumisessa ja aktivaatiossa. Normaalisti Bcl-10 ilmentyy vain 
sytoplasmassa. Bcl-10:n yli-ilmentyminen ja erityisesti tumailmentyminen vaikuttavat osallistuvan 
eräiden lymfoomien patogeneesiin.
Tutkimuksemme tavoitteena oli selvittää Bcl-10:n ja erityisesti sen tumailmentymisen yleisyyttä ja 
vahvuutta diffuusin suurisoluisen B-solulymfooman primaareissa ja sekundaareissa 
keskushermostotapauksissa. Aineistomme koostui 58 lymfoomatapauksesta Tampereen 
yliopistosairaalasta vuosilta 1993 – 2012. Näistä 51 oli primaareja ja 7 sekundaareja tapauksia; 
primaareista 45 paikallistui aivoihin ja 6 selkäytimeen.
Bcl-10 ilmentyi isossa osassa tapauksista. Ilmentyminen tumassa oli selvästi yleisempää ja 
vahvempaa kuin sytoplasmassa (p<0,001). Sekundaarit tapaukset ilmensivät Bcl-10:ä tumassa 
enemmän kuin primaarit (p=0,006). Primaarien aivo- ja selkäydinlymfoomien välillä ei havaittu 
tällä otoksella tilastollisesti merkittävää eroa.
Tuloksemme osoittavat, että Bcl-10:n tumailmentyminen on yleistä keskushermostolymfoomissa. 
Tämä luo pohjan tuleville tutkimuksille Bcl-10:n tumailmentymisen tarkemmasta roolista 
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A DESCRIPTIVE STUDY: NUCLEAR EXPRESSION OF BCL10 IN 
PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM 
LYMPHOMAS
SUMMARY
Bcl10 is a signalling molecule known to play an important role in cell survival. Bcl10 expression 
has proved out to be common in several types of lymphomas. Further more nuclear Bcl10 
expression is shown to be a sign of advanced disease in mucosa-associated lymphatic tissue 
(MALT) lymphomas. We have done a descriptive study of  Bcl10 expression in primary and 
secondary central nervous system (CNS) lymphomas with an emphasis on nuclear expression. 
Bcl10 was immunostained in 58 diffuse large B cell CNS lymphoma cases (51 primary and 7 
secondary) from Tampere University Hospital from the years 1993-2012. They showed a great 
portion of nuclear Bcl10 expression, secondary cases even more than primary ones (p=0.006). To a 
lesser extent also cytoplasmic Bcl10 expression was observed. So far little is known about Bcl10 
expression in central nervous system lymphomas. This study shows a significant overall expression 
of Bcl10 in CNS lymphomas, which might play an important role in their pathogenesis. Moreover, 
there seems to be a significant difference of cytoplasmic and nuclear staining when compared to 
systemic lymphomas based on published data.
1 INTRODUCTION
Although central nervous system lymphoma is a rare disease, during the last decades its incidence 
has been growing (1). In Finland there are approximately 1300 new lymphoma cases diagnosed 
every year (1), and 1 – 2 % of them are primary central nervous system lymphomas (PCNSL) (2). 
Most of PCNSLs (97 %) are diffuse large B-cell lymphomas (DLBCL) (1). Primary spinal cord 
lymphoma is a rare form of PCNSL: 1 % to 2 % of PCNSLs locate in the spinal cord (3).  On the 
other hand, 5 % of systemic DLBCLs metastasize in the central nervous system (4).
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Bcl10 molecule is part of the lymphocyte activation and immune response through B cell receptors. 
Normally Bcl10 acts together with MALT1 and CARMA1 proteins in the cytoplasm as a part of a 
signalling pathway that activates NF-κB transcription which leads to prolonged cell survival (5).
Nuclear expression of Bcl10 has been observed in MALT, follicular, nodal and extranodal DLBCL 
lymphomas and in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (6–8 ), but its 
role in their pathogenesis is not known. Among normal tissues Bcl10 is expressed only in lymphoid 
tissue and in breast tissue, predominantly in the cytoplasm (7). Since nuclear Bcl10 staining is 
almost explicitly related to lymphoma cells, it seems to be of importance. In gastric MALT 
lymphomas nuclear Bcl10 expression is a sign of advanced disease (9).
Overall cellular Bcl10 overexpression seems to be more common in extranodal than in nodal 
DLBCLs (6). Expression of Bcl10 is not so far thoroughly studied in CNS lymphomas, thus data 
available is very limited.  Courts et al. suggested that Bcl10 is underexpressed in PCNSLs when 
compared to normal reactive GCB cells, indicating an abnormal, Bcl10 independent activation 
pathway for NF-kB (10). However, nuclear and cytoplasmic Bcl10 expression was not evaluated 
separately, which has been shown to be of major importance when investigating its role in 
signalling pathways (7, 9, 11–12). Until now there have not been any publications about nuclear 
Bcl10 in central nervous system lymphomas, or studies comparing the expression of Bcl10 in 
PCNSL with that in secondary central nervous system lymphomas (SCNSL) of DLBCL type. 
Pathogenesis of spinal cord lymphomas has also not been documented throughly, although clinical 
studies and case reports are published (13–15). We have performed a descriptive study of the 
expression of Bcl10 in PCNSL and SCNSL and on the other hand in primary brain lymphomas and 
primary spinal cord lymphomas, which seems like playing an important role in pathogenesis of 
these disease entities.
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2 MATERIALS AND METHODS
2.1 Materials
All CNS-DLBCL cases diagnosed in Tampere University Hospital during the years 1993–2012 
were gathered. Of those 74 patients 14 were excluded because of lack of tissue material available, 1 
because of lack of information whether it was primary or secondary case, and 1 because of technical 
problems, leaving 58 cases for analysis: 51 primary and 7 secondary CNS lymphomas. When we 
divided the PCNSLs further into subgroups according to their location, there were 45 brain 
lymphomas and 6 spinal cord lymphomas. Tissue biopsies were taken for diagnosis before 
treatment, and formalin-fixed, paraffin-embedded blocks were made. We constructed tissue 
microarray blocks with three representative cores per patient, diameter 1.5 mm.
16 (27.6 %) of the samples were from female patients and 42 (72.4 %) of male patients. Table 1 
shows the sex and age distribution in the entire cohort and in the subgroups.
2.2 Immunohistochemical analysis
We used Bond-max™ automated immunostainer (Vision BioSystems Ltd, Newcastle, UK) for 
staining procedure. Sections were deparaffinized in Bond™ Dewax Solution, rehydrated in a graded 
ethanol series, and heat-induced antigen retrieval was performed in EDTA based buffer (Bond™ 
Epitope Retrieval Solution 2, pH 9.0, 30 min). The following mouse monoclonal antibodies were 
used: CD-10 (Novocastra™, dilution 1:70) Bcl-6 (Novocastra™, dilution 1:200), MUM-1 
(DakoCytomation, dilution 1:200), and Bcl-10 (Zymed® Laboratories, dilution 1:80).
As positive controls we used normal appendix for CD-10 and Bcl-6, normal tonsil for Bcl-10 and 
extranodal marginal zone B-cell lymphoma for MUM-1. Unlabeled (negative) cases of the same 
tissue microarray block served as negative controls.
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Tumors were categorized into four groups based on immunostaining intensity: negative (<10 % of 
tumor cells labeled), 1+ (10–33 %), 2+ (33–66 %) and 3+ (>66 %). We used the mean of three 
cores of each patient for the analysis. For Bcl-6 and MUM-1 both cytoplasmic and nuclear 
positivity were required, and for CD-10 only membrane staining was considered positive. For Bcl10 
cytoplasmic and nuclear staining were evaluated separately.
2.3 Statistical analysis
The programming language R 3.0.2 was used for the analysis. Mann-Whitney U test was used to 
assess the differences in immunostaining of Bcl10, CD10, Bcl6 and MUM1 between the subgroups 
and the differences between nuclear and cytoplasmic Bcl10 expression. Spearman's rank order 
correlation was used to assess whether nuclear and cytoplasmic staining of Bcl10 correlated with 
each other. P values of <0.05 were considered statistically significant.
3 RESULTS
Table 2 and Figure 1 show the expression of cytoplasmic and nuclear Bcl-10 in primary and 
secondary central nervous system lymphomas and in primary brain and spinal cord lymphomas. 
Approximately 2/3 of our lymphomas showed only weak or no cytoplasmic staining of Bcl10 
(median=0.67). In primary cases cytoplasmic Bcl10 expression was stronger than in secondary 
cases (p=0.024). Among PCNSLs, brain lymphomas seemed to show more cytoplasmic staining 
than spinal cord lymphomas (p=0.051).
Nuclear staining of Bcl10 was overall more common and stronger than cytoplasmic (median=2) 
(Table 2, Table 3). All our secondary cases showed high (x > 2) nuclear expression of Bcl10, and 
the expression was thus significantly stronger than in primary ones (p=0.006). Among PCNSLs, 
there was no difference between brain and spinal cord cases.
Next we tried to figure out the correlation of nuclear Bcl10 positivity to cytoplasmic Bcl10 
positivity. We could not find any clear correlation between nuclear and cytoplasmic expression of 
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Bcl10, neither in the whole sample nor in the subgroups. Thus, expression of Bcl10 nuclearly was 
not necessarily accompanied by cytoplasmic expression, or vice versa (Table 4).
Nuclear and cytoplasmic Bcl10 expression did not depend on age or sex (data not shown).
In addition to Bcl10, also Bcl6, MUM1 and CD10 were studied, as these markers are known to be 
expressed on lymphoma cells in general. Among these only significant difference was found with 
MUM1 expression. MUM1 is expressed more in primary brain lymphomas when compared to 
primary spinal cord lymphomas.
4 DISCUSSION
Our samples of primary and secondary CNS lymphomas showed remarkable nuclear Bcl10 
expression. Although cytoplasmic Bcl10 expression was also seen in the samples, compared to the 
nuclear expression, it was less frequent and less intensive. Nuclear expression was stronger in 
secondary cases when compared to primary cases. On the other hand, cytoplasmic expression was 
stronger in primary cases than in secondary cases. These differences proved out to be statistically 
significant, despite of our small number of SCNSLs (n=7). 
As the incidence and prevalence of primary spinal cord lymphomas worldwide is low, our sample 
collection was also small (n=6). Thus, some real differences between primary brain and primary 
spinal cord lymphomas may not have been shown as statistically significant. In future, hopefully 
international study groups will overcome this problem by combining their own sample collections 
for further studies.
We strongly believe that nuclear Bcl10 expression in CNS lymphomas is of great interest. So far, 
our information about nuclear Bcl10 expression comes mostly from MALT lymphomas. In MALT 
lymphomas, nuclear Bcl10 expression is partially related to the translocations t(11;18)(q21;q21) and 
t(1;14)(p22;q32) (16). Nakagawa et al. documented that normally MALT1 transports Bcl10 from 
nucleus to the cytoplasm, and suggested that nuclear Bcl10 expression is caused by failure in this 
transport mechanism (11). T(11;18)(q21;q21) causes the formation of API-MALT1 fusion protein, 
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which no longer transports Bcl10 to the cytoplasm (11, 17), and t(1;14)(p22;q32) causes 
overexpression of Bcl10, resulting in a relative shortage of MALT1 and thus part of Bcl10 staying 
in the nucleus (11). Achuthan et al. (18) suggested that t(1;14)(p22;q32) traslocation involving 
Bcl10 gene is limited to MALT lymphoma cases, but the small sample size (18 lymphomas, of 
which 4 DLBCLs and no PCNSLs) limits the cogency of their results. However, there are also 
MALT lymphoma cases with nuclear Bcl10 staining without above mentioned translocations (16). 
The molecular mechanism for nuclear Bcl10 expression in those cases still remains unclear. 
According to Yeh et al. (19), TNF-α induced NF-κB activation causes overexpression of Bcl10 in 
human breast carcinoma cells, resulting also in its nuclear location. The same mechanism could 
possibly explain a part of the lymphoma cases with nuclear Bcl10. Future studies will solve what 
causes nuclear Bcl10 in CNS lymphomas: whether it is the same translocations as in MALT 
lymphomas, or other reasons.
In our data nuclear and cytoplasmic Bcl10 did not correlate with each other. If nuclear location of 
Bcl10 were caused purely by its overexpression, it should be overexpressed both in nucleus and in 
cytoplasm. Thus, we suggest that not all of the nuclear Bcl10 was caused by its overexpression, but 
also by an aberrant nucleus-cytoplasm transport mechanism.
Yeh et al. (19) found that overexpressed and nuclearly located Bcl10 in their data further acted as a 
transcriptional activator of NF-κB. Also Liu et al. (12) suggested that Bcl10 has transactivation 
activity and thus could cause tumorgenesis by acting as a transcription factor, and Nakagawa et al. 
(11) documented that nuclear Bcl10 and MALT1 location was associated with increased NF-κB 
activation in a cell culture. It is shown that nuclear Bcl10 and NF-κB activation correlate in MALT 
lymphomas (20), but seemingly not in lymphoplasmacytic lymphoma/Waldenström 
macroglobulinemia (8). To the best of our knowledge, correlation between nuclear Bcl10 and NF-
κB activation in other lymphomas has not been studied. It should be investigated, whether nuclear 
Bcl10 expression correlates with NF-κB activation in CNS lymphomas, and if it does, whether there 
is causality and what the causal direction is. Regardless of the molecular mechanism, however, it 
has been proved that nuclear Bcl10 is associated with advanced tumor in gastric MALT 
lymphomas, i.e. non-responsiveness to Helicobacter pylori eradication (9, 21). Thus, nuclear Bcl10 
certainly affects the tumorgenesis of MALT lymphomas, and probably also other lymphomas with 
nuclear Bcl10 expression.
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Little is known about the biology of systemic DLBCLs invading the brain. Although clinical studies 
and even a guideline on the prevention of SCNSLs are published (22–23), so far no biological 
markers for the probability of a brain recurrence of a systemic DLBCL are known. Our study 
suggests that Bcl10 might have a role in SCNSLs, since all our cases showed strong nuclear Bcl10 
expression. In systemic DLBCLs outside the brain nuclear Bcl10 is an existent but not a common 
phenomenon (7, 24). Future studies should be performed to compare Bcl10 expression in SCNSLs 
and other DLBCLs in general. Moreover, it would be interesting to know if the expression profile of 
Bcl10 changes when a systemic DLBCL metastasizes to the CNS. If nuclear Bcl10 proves out to be 
more common in SNCSLs than in other DLBCLs as it now seems, it might be a biological marker 
predicting a CNS involvement of a systemic DLBCL.
The median overall survival time for non-Hodgkin’s lymphoma with CNS involvement has been 
only approximately 2 months in several studies (25–27), while for PCNSLs it is as much as 29 to 51 
months when treated with combined high-dose methotrexate-based chemotherapy and radiation 
therapy (28–29). Because of the heterogeneity of treatments of our patient sample, we could not 
perform any prognostic analysis of nuclear Bcl10. Since all our SCNSLs showed strong nuclear 
Bcl10 expression and they generally have a poor prognosis, we still suggest that it might be a 
prognostic marker in CNS lymphomas and in DLBCLs in general. This will be a subject of future 
studies with a nationwide, more homogeneously treated patient sample.
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Table 1. Sex and age distributions.
All cases (58) PCNSL (51)  Secondary (7) PCNSL brain (45) PCNSL spinal cord (6)
Age, md (range) 65.5 (21-79) 66 (39-79) 56 (21-77) 66 (39-78) 65.5 (44-79) 
Women 27.6 % 29.4 % 14.3 % 31.1 % 16.7 %
Men 72.4 % 70.6 % 85.7 % 68.9 % 83.3 %
Table 2. Bcl10, CD10, Bcl6 and MUM1 expression in the subgroups.









P value md (range)
Bcl10 nuclear 2 (0-3) 3 (2.33-3) 0.006 2 (0-3) 2.83 (1-3) 0.18 2      (0 – 3) 
Bcl10 cytopl. 1 (0-3) 0 (0-2.33) 0.024 1 (0-3) 0   (0-1.5) 0.051 0.67 (0 – 3) 
CD10 0 (0-3) 0.33 (0-3) 0.13 0 (0-3) 0.96 (0-3) 0.025 0      (0 – 3) 
Bcl6 2 (0-3) 1.67 (0-3) 0.27 2 (0-3) 2      (0-3) 0.77 2      (0 - 3)
MUM1 2 (0-3) 2.33 (0-3) 0.78 2 (0-3) 0.5   (0-1) <0.001 2      (0 – 3) 
Table 3. Nuclear and cytoplasmic Bcl10 expression.
Nuclear  (md) Cytoplasmic (md) P value
All 2 0.67 <0.001
PCNSL 2 1 <0.001
SNCSL 3 0 0.001
Primary brain 2 1 0.001
Primary spinal cord 2.83 0 0.011
Table 4. Correlation between nuclear and cytoplasmic Bcl10.




Primary brain 0.41 0.006
Primary spinal cord -0.36 0.48
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Figure 1. Bcl10 positive primary brain (a, b), primary spinal cord (c, d) and secondary brain (e, f) 
lymphoma cases. Original magnification x200.
a, c and e) nuclear +++ b) nuclear +, cytoplasmic +++ d) cytoplasmic ++ f) cytoplasmic +++, 
nuclear +++.
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